Antiangiogenesis Agents

Many of the agents described in the above sections, such as the FTIs, TKIs, and ATO, exhibit multiple modes of action, including regulation of VEGF activity.

Thalidomide is an antiangiogenesis agent that inhibits cellular response to VEGF and proliferation of cells that express the VEGF receptor, and also has significant anti-TNF properties. Thalidomide and its analogs are described below. Other agents that have shown activity in a subset of low-risk patients include matrix metalloprotease inhibitors, which block the end results of VEGF's paracrine effects, i.e., extracellular matrix degradation, and the monoclonal antibody to VEGF, bevacizumab.

0 0

Post a comment